Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib monotherapy for recurrent or persistent cervical squamous cell carcinoma after failure of chemoradiotherapy or other targeted therapy
ChiCTR1900021506Phase 4Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Mar 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in cervical squamous cell carcinoma (CSCC), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on ChiCTR1900021506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021506.